The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...

Regeneron Canada, a biotechnology company focused on developing treatments for serious diseases, has reached a pricing and funding agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...

“Under the theme “Designing Future Society for Our Lives,” the Expo will address eight key thematic areas focused on global challenges, providing an exceptional platform for PNG to showcase its trade ...

The Business Research Company Updated 2025 Market Reports have released and offer essential trends and forecasts up to 2034. Early purchase is your competitive edge! LONDON, GREATER LONDON, UNITED KIN ...

Combination therapies, such as Regeneron’s Libtayo (cemiplimab) and Merck’s Keytruda (pembrolizumab), are creating new treatment possibilities for advanced skin cancers, including basal cell carcinoma ...

After hours: 20 March at 19:51:30 GMT-4 Loading Chart for REGN ...

Get the latest news delivered straight to your inbox!